Molecular Testing in Ovarian Tumours: Challenges from the Pathologist’s Perspective
Open Access
- 15 June 2023
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 13 (12) , 2072
Abstract
The use of molecular testing to direct diagnosis and treatment options in ovarian tumours has rapidly expanded in recent years, in particular with regard to the recommendation for routine homologous recombination deficiency (HRD) testing in all patients with high-grade ovarian epithelial tumours. The implications of this increased level of testing upon the pathologist is significant in terms of increased workload, the provision of adequate tumour samples for molecular testing, and the interpretation of complex molecular pathology reports. In order to optimise the quality of reports generated, it is important to establish clear pathways of communication on both a local and national level between clinicians, pathology lab staff, and medical scientists. On a national level, in the United Kingdom, Genomic Laboratory Hubs (GLHs) have been established to provide a uniform high-quality molecular diagnostics service to all patients with ovarian tumours within the National Health services in the country. On a local level, there are a number of small steps that can be taken to improve the quality of tissues available for testing and to streamline the processes involved in generating requests for molecular testing. This article discusses these factors from the perspective of the clinical histopathologist.Keywords
This publication has 53 references indexed in Scilit:
- Prognostically relevant gene signatures of high-grade serous ovarian carcinomaJournal of Clinical Investigation, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- KIT gene mutation and amplification in dysgerminoma of the ovaryCancer, 2010
- ARID1AMutations in Endometriosis-Associated Ovarian CarcinomasNew England Journal of Medicine, 2010
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovaryThe Journal of Pathology, 2010
- Mutation ofFOXL2in Granulosa-Cell Tumors of the OvaryNew England Journal of Medicine, 2009
- Mouse Model of Human Ovarian Endometrioid Adenocarcinoma Based on Somatic Defects in the Wnt/β-Catenin and PI3K/Pten Signaling PathwaysCancer Cell, 2007
- Mutation of the PIK3CA Gene in Ovarian and Breast CancerCancer Research, 2004
- Carcinosarcomas (Malignant Mullerian Mixed Tumors) of the Uterus and Ovary: A Genetic Study With Special Reference to HistogenesisInternational Journal of Gynecological Pathology, 2003